Oyster Point Pharma, Inc.

Two years after Viatris Inc. was established from the merger of Mylan Pharmaceuticals Inc. with Pfizer Inc. 's Upjohn business, the former generics company is getting ready to begin the second ph

The difference between fundraising by private biopharmaceutical companies and publicly traded drug developers has been stark in 2022. In fact, the last few days of June were emblematic of the long lag

Manufacturing inspections remain a sore spot for new drug and biologic applications, both because the COVID-19 pandemic still impeding the ability of inspectors to travel to facilities and because ins

There are five novel agents with October 2021 goal dates on the FDA’s user fee calendar, but at least one – Omeros Corporation ’s narsoplimab – already appears unlikely to see a decision, let alone a